Monitor the May 14 investor meeting for new biomarker and immunologic data on soquelitinib, which could influence investor sentiment ahead of the Phase 3 readout in PTCL. Absence of a Q1 earnings call suggests limited near-term financial updates.
Price Chart
Executive Summary
Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soquelitinib in atopic dermatitis, including late-breaking data on drug-free remissions, presented at the Society for Investigative Dermatology meeting. The company will report Q1 2026 financial results on May 7 but will not hold a conference call.
Key Facts
- Investor and analyst meeting scheduled for May 14, 2026, to discuss soquelitinib Phase 1 data from the SID Annual Meeting.
- Two oral presentations at SID include a late-breaking session on drug-free remissions with soquelitinib.
- Phase 1 trial data is from a randomized, blinded, placebo-controlled study in moderate-to-severe atopic dermatitis.
- Company to release Q1 2026 financial results on May 7, 2026, without a conference call or webcast.
- Soquelitinib is an oral, selective ITK inhibitor currently in Phase 3 for relapsed/refractory PTCL and Phase 2 for atopic dermatitis.
Financial Impact
No financial data disclosed in this release; financial results expected May 7.
Risk Factors
- Clinical data may not translate into meaningful efficacy in later-stage trials.
- No conference call for Q1 results may limit transparency and investor engagement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277804 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $14.46 $12.42 | ▼ −14.11% | ▼ −13.58% | $10.90 (−24.62%) |
Jul 22, 2026 10w ago | 8-K | $13.68 $14.33 | ▲ +4.75% | ▲ +1.44% | $10.90 (−20.32%) |
Jun 11, 2026 16w ago | Institutional Cluster | $11.60 $16.20 | ▲ +39.66% | ▲ +37.76% | $10.90 (−6.03%) |
May 14, 2026 20w ago | 8-K | $13.66 $11.93 | ▼ −12.63% | ▼ −11.77% | $10.90 (−20.18%) |
May 7, 2026 21w ago | 8-K | $15.55 $11.12 | ▼ −28.49% | ▼ −28.51% | $10.90 (−29.90%) |
Apr 24, 2026 23w ago | DEFA14A | $15.92 $12.83 | ▼ −19.41% | ▼ −24.37% | $10.90 (−31.53%) |
Apr 21, 2026 23w ago | Press Release | $17.14 $12.21 | ▼ −28.76% | ▼ −33.68% | $10.90 (−36.41%) |
Mar 12, 2026 29w ago | Press Release | $15.32 $15.17 | ▼ −0.98% | ▼ −4.57% | $10.90 (−28.85%) |
Mar 5, 2026 30w ago | Press Release | $15.80 $14.71 | ▼ −6.87% | ▼ −4.82% | $10.90 (−30.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access